Results 321 to 330 of about 22,544,156 (338)

Hyperkalemia and maintenance of renin-angiotensin system inhibitor therapy after initiating SGLT-2 or DPP-4 inhibitors. [PDF]

Nephrol Dial Transplant
Bosi A, Xu Y, Faucon AL, Huang T, Evans M, Shin JI, Fu EL, Carrero JJ.   +7 more
europepmc   +1 more source

Proteins and signalling pathways targeted by dapagliflozin and finerenone: Insights from DAPA‐CKD and FIGARO‐DKD

Diabetes, Obesity and Metabolism, EarlyView.
Mark André de la Rambelje, Adriaan A. Voors, Peter J. Greasley, Mario Berger, Hiddo J. L. Heerspink   +4 more
wiley   +1 more source

Efficacy of luseogliflozin for renal function preservation in patients with type 2 diabetes mellitus and impaired renal function: A randomized open‐label clinical trial (RESOLUTION study)

Journal of Diabetes Investigation, EarlyView.
Luseogliflozin alleviated renal function decline (eGFR) after an initial decrease, showing renoprotective effects in patients with renal impairment. Luseogliflozin did not increase renal events, showing safety even in patients with moderate‐to‐severe renal impairment.
Munehiro Kitada, Masao Toyoda, Osamu Sekine, Daisuke Suzuki, Yosuke Okada, Yoshikata Morita, Hideki Nishimura, Hiroaki Satoh, Hideki Kamiya, Toshinari Takamura, Motohide Isono, Takeshi Onoue, Hiroshi Arima, Kenichi Tanaka, Masaji Miyamoto, Yasushi Omura, Daisuke Yabe, Takehiro Kato, Akimichi Asano, Yutaka Wakasa, Satoshi Miyamoto, Shinji Kume, Tomohiko Ito, Shin‐ichi Araki, Atsushi Nakagawa, RESOLUTION Study Investigators   +25 more
wiley   +1 more source

Research Progress of Food-Derived Antihypertensive Peptides in Regulating the Key Factors of the Renin-Angiotensin System. [PDF]

Nutrients
Yao X, Cao X, Chen L, Liao W.
europepmc   +1 more source

Protective association of renin‐angiotensin system inhibitor use with skeletal muscle wasting in diabetic heart failure

Journal of Diabetes Investigation, EarlyView.
In heart failure, renin‐angiotensin system inhibitor (RASI) use was associated with less skeletal muscle wasting in patients with diabetes, but not in those without diabetes (significant interaction). The association in diabetes was more evident at lower plasma 3‐methylhistidine levels than at higher levels, suggesting a potential biomarker‐defined ...
Hidemichi Kouzu, Toshiyuki Yano, Satoshi Katano, Wataru Kawaharata, Ryo Numazawa, Ryohei Nagaoka, Hiroki Aida, Katsuhiko Ohori, Takefumi Fujito, Nobutaka Nagano, Masato Furuhashi   +10 more
wiley   +1 more source

Phosphoproteomics for studying signaling pathways evoked by hormones of the renin-angiotensin system: A source of untapped potential. [PDF]

Acta Physiol (Oxf)
Souza-Silva IM, Carregari VC, Steckelings UM, Verano-Braga T.   +3 more
europepmc   +1 more source

Impact of sotagliflozin on glomerular hyperfiltration in people with type 1 diabetes: A post hoc analysis of the inTandem3 trial

Diabetes, Obesity and Metabolism, EarlyView.
Amrit Pathak, M. Belinda Hardin, Manon Girard, Michael J. Davies, William B. Horton   +4 more
wiley   +1 more source

GLP‐1 Receptor Agonist Therapy and Cardiorenal Outcomes in Patients ≥ 80 Years Old With Type 2 Diabetes

Journal of the American Geriatrics Society, EarlyView.
Effect of glucagon‐like peptide‐1 receptor agonist therapy on cardiorenal outcomes in patients aged ≥ 80 years with Type 2 diabetes. ABSTRACT Background Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have demonstrated potential in improving glycemic control and reducing adverse outcomes in patients with Type 2 diabetes mellitus (T2DM); however ...
Jui‐Cheng Chen, Yu‐Wei Fang, Ya‐Fang Liu, Mon‐Ting Chen, Ming‐Hsien Tsai   +4 more
wiley   +1 more source

Effects of agents acting on the renin-angiotensin system on the incidence of gastric cancer: A two-sample Mendelian randomization study. [PDF]

Medicine (Baltimore)
Lu H, Lu H, Li F, Zhao D.
europepmc   +1 more source

Carfilzomib-specific proteasome β5/β2 inhibition drives cardiotoxicity via remodeling of protein homeostasis and the renin-angiotensin-system. [PDF]

iScience
Mendez-Lopez M, Besse A, Zuppinger C, Perez-Shibayama C, Gil-Cruz C, Florea BI, De Martin A, Lütge M, Beckerova D, Klimovic S, Zhou X, Rasche L, Pribyl J, Rotrekl V, Ludewig B, Overkleeft HS, Besse L, Driessen C.   +17 more
europepmc   +1 more source